Moors & Cabot Inc. Has $4.25 Million Holdings in Bristol-Myers Squibb Company (BMY)
Moors & Cabot Inc. boosted its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 4.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,114 shares of the biopharmaceutical company’s stock after purchasing an additional 3,235 shares during the period. Bristol-Myers Squibb makes up 0.7% of Moors & Cabot Inc.’s holdings, making the stock its 25th biggest holding. Moors & Cabot Inc.’s holdings in Bristol-Myers Squibb were worth $4,252,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC grew its holdings in shares of Bristol-Myers Squibb by 108.5% in the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock valued at $751,563,000 after purchasing an additional 7,020,200 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Bristol-Myers Squibb by 185.2% in the second quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock valued at $339,830,000 after purchasing an additional 3,960,191 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Bristol-Myers Squibb by 2,990.5% in the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock valued at $202,494,000 after purchasing an additional 3,516,536 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Bristol-Myers Squibb by 18.7% in the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock valued at $845,504,000 after purchasing an additional 2,451,390 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Bristol-Myers Squibb by 2.4% in the second quarter. BlackRock Inc. now owns 99,454,602 shares of the biopharmaceutical company’s stock valued at $5,541,612,000 after purchasing an additional 2,367,864 shares in the last quarter. 69.82% of the stock is currently owned by institutional investors.
BMY has been the subject of a number of research reports. Cowen set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, August 14th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.08 price objective for the company in a report on Thursday, August 17th. Jefferies Group restated a “buy” rating and issued a $66.00 price objective (up previously from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. Finally, BMO Capital Markets restated a “sell” rating and issued a $49.00 price objective on shares of Bristol-Myers Squibb in a report on Monday, September 4th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $64.93.
Bristol-Myers Squibb Company (BMY) opened at $63.53 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a market cap of $102,146.62, a P/E ratio of 21.08, a price-to-earnings-growth ratio of 2.37 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 EPS. equities analysts forecast that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Stockholders of record on Friday, January 5th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is currently 61.42%.
In other news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.23% of the stock is currently owned by insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.